The role of Hypoxia-Inducible Factor-1alpha and its signaling in melanoma - 03/09/21
pages | 9 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Adaptation to the loss of O2 is regulated via the activity of hypoxia-inducible factors such as Hypoxia-Inducible Factor-1 (HIF-1). HIF-1 acts as a main transcriptional mediator in the tissue hypoxia response that regulates over 1000 genes related to low oxygen tension. The role of HIF-1α in oncogenic processes includes angiogenesis, tumor metabolism, cell proliferation, and metastasis, which has been examined in various malignancies, such as melanoma. Melanoma is accompanied by a high death rate and a cancer type whose incidence has risen over the last decades. The linkage between O2 loss and melanogenesis had extensively studied over decades. Recent studies revealed that HIF-1α contributes to melanoma progression via different signaling pathways such as PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, JAK/STAT, Wnt/β-catenin, Notch, and NF-κB. Also, various microRNAs (miRs) are known to mediate the HIF-1α role in melanoma. Therefore, HIF-1α offers a diagnostic/prognostic biomarker and a candidate for targeted therapy in melanoma.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | HIF-1 (HIF-1β/HIF-1α) is an O2 homeostasis and hypoxia transcriptional regulator. |
• | HIF-1α mediates progressive melanomagenesis processes via several signaling pathways. |
• | MicroRNAs have inhibitory or promotive effects on HIF-1α expression in melanoma. |
• | HIF-1α could be a diagnostic/prognostic biomarker and treatment target in melanoma. |
Keywords : Hypoxia, HIF-1α, Melanoma, Signaling pathways, Diagnostic/prognostic biomarker, Melanoma treatment
Plan
Vol 141
Article 111873- septembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?